Mistol vaginal suppositories are used for the local treatment of trichomonas and nonspecific vaginitis.
Composition
The active substance is metronidazole (1 suppository contains 0.1 g of metronidazole).
The excipient is solid fat.
Contraindication
Hypersensitivity to metronidazole or other components of the drug; hypersensitivity to imidazole derivatives; in combination with disulfiram or alcohol.
Method of application
The drug is allowed to be used for the treatment of adult patients only.
It is absolutely necessary to simultaneously treat the patient's sexual partner, even if he has no symptoms of infection.
The maximum duration of treatment with Mistol should not exceed 10 days, and the number of treatment courses should be 2-3 per year.
Application features
Pregnant women
Animal studies have not shown a teratogenic effect. Since no teratogenic effect has been observed in animals, no malformations are expected in humans. According to the data, substances that cause malformations in humans have a teratogenic effect in animals in adequately conducted studies in two species. Clinical data have not demonstrated any specific teratogenic or fetotoxic effects associated with metronidazole. However, the absence of such a risk can only be confirmed by epidemiological studies. In this regard, metronidazole should be prescribed during pregnancy only if necessary.
Children
Contraindicated.
Drivers
If dizziness, confusion, hallucinations, seizures, or temporary visual impairment are observed during treatment, you should refrain from driving vehicles and operating other mechanisms.
Overdose
Leukopenia, neuropathy, ataxia, vomiting, mild disorientation may occur. Since a specific antidote to metronidazole is unknown, symptomatic therapy is recommended.
Side effects
From the blood and lymphatic system: very rarely - agranulocytosis, neutropenia, thrombocytopenia, pancytopenia and leukopenia. Hypersensitivity reactions: skin rashes with hyperemia, itching, redness, urticaria, erythema multiforme; flushing, fever, angioedema, exceptional cases of anaphylactic shock, isolated cases of pustular rash, toxic epidermal necrolysis, fixed toxicoderma, Lyell's syndrome, Stevens-Johnson syndrome. From the central and peripheral nervous system: peripheral sensory neuropathy, headache, convulsions, dizziness, ataxia, drowsiness, aseptic meningitis; encephalopathy (confusion, fever, increased sensitivity to light, torticollis, hallucinations, paralysis, visual and movement disorders), and subacute cerebellar syndrome (ataxia, dysarthria, gait disturbance, tremor, nystagmus), which may resolve after discontinuation of the drug. Psychiatric disorders: mental disorders, including confusion, hallucinations, psychotic reactions with paranoia and/or delirium, which may rarely be accompanied by suicidal thoughts or suicide attempts; depressed depressive mood. On the part of the organs of vision: temporary disturbances of visual functions, such as diplopia, myopia, blurred vision, decreased visual acuity, changes in color perception; optic neuropathy/neuritis. Hepatobiliary system: increased levels of liver enzymes (ACT, ALT, LF), cholestatic or mixed hepatitis and damage to liver cells (hepatocytes), sometimes with jaundice; cases of liver failure requiring liver transplantation have been reported in patients treated with metronidazole and other antibiotics. Genitourinary system: urine may be stained brown-red due to the presence of pigments associated with the metabolism of metronidazole; with prolonged treatment, excessive development of vaginal fungal flora (candidiasis) is sometimes observed, requiring the appointment of antifungal drugs. Digestive system: minor disorders of the gastrointestinal tract (epigastric pain, nausea, vomiting, diarrhea); inflammation of the oral mucosa, taste disorders (metallic taste in the mouth), glossitis with dry mouth, stomatitis, coated tongue, discoloration or change in appearance of the tongue (mycosis), anorexia, pancreatitis, which is reversible. Musculoskeletal and connective tissue disorders: myalgia, arthralgia. Hearing and balance disorders: hearing impairment/hearing loss (including sensorineural hearing); tinnitus. Other adverse reactions: fever.
Interaction
Disulfiram: Cases of acute transient delusional disorders (acute delirium, confusion) have been reported in patients taking metronidazole and disulfiram concomitantly.
Alcohol. You should not drink alcoholic beverages or take medications containing alcohol during treatment and for at least one day after its completion due to the possible occurrence of a disulfiram-like (Antabuse) effect (hot flashes, erythema, vomiting, tachycardia).
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life - 2 years.
